Macquarie Group’s Immunome IMNM Stock Holding History

Macquarie Group’s Portfolio IMNM Stock Details IMNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-3,518	Closed	-$87	–	2004
2024 Q1	$87	Buy	+3,518	New	+$71.4K	﹤0.01%	1640

Other funds holding IMNM

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Macquarie Group's IMNM Position: Q2 2024 in Review

Macquarie Group sold out of Immunome (IMNM) in Q2 2024, closing a stake of 3,518 shares — an estimated $87 sold.

Macquarie Group first reported a position in IMNM in Q1 2024 and held it in 1 quarter. The position peaked at $87 in Q1 2024. 113 funds tracked by Wall St. Rank hold IMNM as of Q2 2024.

Macquarie Group reported no remaining Immunome position as of Q2 2024 after selling out during the quarter.
Macquarie Group sold 3,518 Immunome shares in Q2 2024, an estimated $87.
Macquarie Group first reported a position in Immunome in Q1 2024 and held it in 1 quarter.
Macquarie Group's Immunome position peaked at $87 in Q1 2024.
113 funds tracked by Wall St. Rank held Immunome as of Q2 2024.

Based on Macquarie Group's 13F filing for Q2 2024, filed 9 Aug 2024.